Dr. Greten on Promising Immunotherapy Agents in HCC

Tim F. Greten, MD
Published: Friday, May 19, 2017



Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute, discusses promising immunotherapy agents being investigated in hepatocellular carcinoma (HCC).

The immunotherapy that is furthest developed in this space is nivolumab (Opdivo), which is being investigated in a phase III study, explains Greten.
,br> Additionally, cell-based therapies are being looked at but they are harder to investigate as there are very little data to analyze, states Greten.

Chimeric antigen receptor (CAR) T-cell therapy has not been very successful in solid cancers but it is 1 of the future areas that will be studied for patients with HCC.



Tim F. Greten, MD, senior investigator thoracic and gastrointestinal oncology branch, head, gastrointestinal malignancy section, National Cancer Institute, discusses promising immunotherapy agents being investigated in hepatocellular carcinoma (HCC).

The immunotherapy that is furthest developed in this space is nivolumab (Opdivo), which is being investigated in a phase III study, explains Greten.
,br> Additionally, cell-based therapies are being looked at but they are harder to investigate as there are very little data to analyze, states Greten.

Chimeric antigen receptor (CAR) T-cell therapy has not been very successful in solid cancers but it is 1 of the future areas that will be studied for patients with HCC.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x